JAK2V617F allele burden is associated with transformation to myelofibrosis

References

• Baxter EJ, Scott LM, Campbell PJ, . Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054–1061.
   PubMed Web of Science ®Google Scholar
• Jones AV, Kreil S, Zoi K, . Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005;106:2162–2168.
   PubMed Web of Science ®Google Scholar
• Kralovics R, Passamonti F, Buser AS, . A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779–1790.
   PubMed Web of Science ®Google Scholar
• James C, Ugo V, Le Couedic JP, . A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144–1148.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2007;22: 14–22.
   PubMed Web of Science ®Google Scholar
• Chan D, Koren-Michowitz M. Update on JAK2 inhibitors in myeloproliferative neoplasm. Ther Adv Hematol 2011;2:61–71.
   PubMedGoogle Scholar
• Scott LM, Scott MA, Campbell PJ, . Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 2006;108:2435–2437.
   PubMed Web of Science ®Google Scholar
• Nussenzveig RH, Swierczek SI, Jelinek J, . Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol 2007;35:32–38.
   PubMed Web of Science ®Google Scholar
• Moliterno AR, Williams DM, Rogers O, . Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens. Exp Hematol 2008;36:1480–1486.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Rumi E, Pietra D, . A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010;24:1574–1579.
   PubMed Web of Science ®Google Scholar
• Silver RT, Vandris K, Wang YL, . JAK2V617F allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. Leuk Res 2011;35:177–182.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Schwager SM, . The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 2006;106:631–635.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Strand JJ, Lasho TL, . Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera. Leukemia 2007;21:2074–2075.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Antonioli E, Guglielmelli P, . Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden. Leukemia 2007;21:1952–1959.
   PubMed Web of Science ®Google Scholar
• Chaiter Y, Brenner B, Aghai E, . High incidence of myeloproliferative disorders in Ashkenazi Jews in Northern Israel. Leuk Lymphoma 1992;7:251–255.
   PubMed Web of Science ®Google Scholar
• Najean Y, Rain JD, Billotey C. Epidemiological data in polycythaemia vera: a study of 842 cases. Hematol Cell Ther 1998;40:159–165.
   PubMedGoogle Scholar
• Koren-Michowitz M, Shimoni A, Vivante A, . A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD). Leuk Res 2008;32:421–427.
   PubMed Web of Science ®Google Scholar
• Benjamini O, Koren-Michowitz M, Amariglio N, . Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation. Leukemia 2008;22:1961–1963.
   PubMed Web of Science ®Google Scholar
• Sirhan S, Lasho TL, Hanson CA, . The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea. Am J Hematol 2008;83: 363–365.
   PubMed Web of Science ®Google Scholar
• Alvarez-Larrán A, Bellosillo B, Martínez-Avilés L, . Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients. Br J Haematol 2009;146:504–509.
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab O, Manshouri T, Patel J, . Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 2010;70:447–452.
   PubMed Web of Science ®Google Scholar
• Theocharides A, Boissinot M, Girodon F, . Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 2007; 110:375–379.
   PubMed Web of Science ®Google Scholar